stockrow
Monday 9 November 2026
Export IMRX’s income statement to Excel — free account
Immuneering Corporation
IMRXImmuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00.
- EPS
- +1.61%
- Free cash flow
- −40.2%
Quarter to September 2026, against a year earlier
3.68
0.31
+9.20%
Follow IMRX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (33.53%) | (52.15%) | (43.84%) | (43.12%) |
+8 more TTM periods Free account |
|
| (31.40%) | (47.31%) | (41.01%) | (39.36%) | ||
ROIC |
(198.38%) | (97.14%) | (74.29%) | (81.29%) | |
Return on Tangible Assets |
(47.26%) | (37.99%) | (34.59%) | (33.53%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.96) | (0.88) | (0.77) | (1.03) | |
Free Cash Flow |
(61.81) | (56.99) | (49.91) | (45.49) | |
Capital Expenditures |
(0.25) | (0.24) | (0.21) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(19.68%) | (16.73%) | (13.74%) | (11.62%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 0.99 | 0.91 | 0.81 | |
Depreciation/Fixed assets |
(0.95) | (0.49) | 0.15 | 0.58 | |
Capex/Depreciation |
0.32 | 0.56 | (1.49) | (0.26) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.95) | (0.88) | (0.77) | (1.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026